By Matt GrossmanBionomics Ltd. has started on a Phase 2 trial testing the use of a drug to treat social anxiety disorder, the Australian pharmaceutical company said Monday. The drug, called BNC210, will be given to randomly chosen members of the study group. The rest will receive a placebo. The people in the study will then do a public-speaking task meant to prompt anxiety. Results are expected by the end of the year, Bionomics said.

Source: Wall Street Journal January 03, 2022 11:14 UTC